Clinical Trials · NCT06662383
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 800
- Start date
- Nov 2024
- Locations
- 65 sites, 5 countries
- Primary endpoint
- Percent Change from Baseline in Body Weight